Drug Developed at University of Montana by Inimmune Corp. Moves to Cancer Patient Trials

A compound discovered by the University of Montana Center for Translational Medicine has started Phase I clinical trials with cancer patients. The center’s partner in the effort is Inimmune Corp., a Missoula-based biotechnology company.

Jay Evans, a UM researcher and director of the center, said reaching human clinical trials is a milestone for the University and highlights the importance of research at UM.

“Since we joined UM in 2016, it’s been our goal to advance UM research discoveries to treatments that can be safely used in people,” Dr. Evans said. “The transition from pre-clinical to clinical stage of drug development is challenging, and it’s been great to partner with a local Missoula company and advance a university-discovered technology to human clinical trials.”